Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2020

View Archived Issues

Bayer presents data from the phase II FOXTROT study of osocimab

First-in-human data for NEO-201 in chemoresistant solid tumors

NHP model of Ebola virus infection via mucosal challenge

CureVac and CEPI collaborate to develop vaccine against coronavirus nCoV-2019

Follicum receives grant to study binding of FOL peptides to pancreatic cell receptors

Promising results presented for leronlimab in patients with breast cancer

Vaccitech presents data from the FLU009 phase II study of its VTP-100 vaccine

Adapting NGS for coronavirus surveillance

Long QT genes mostly short on evidence

Immunotherapy combination shows promise in NSCLC

Preclinical data lead to clinical study of in derazantinib in advanced gastric cancer

Exelixis presents phase Ib data for XL-888 plus pembrolizumab in advanced gastrointestinal cancer

Voronoi patents new protein kinase inhibitors

GlaxoSmithKline discloses CREB2 inhibitors

Gilead Sciences describes new IRAK-4 inhibitors

Rodin Therapeutics divulges HDAC inhibitors

Eli Lilly and Company presents SERD inducers for cancer

DB-020 prevents cisplatin-induced hearing loss in animal model, enters clinical trial

Calibr begins first-in-human study of CCW-702 in metastatic castration-resistant prostate cancer

Eisai initiates phase II study of E-7090 in advanced cholangiocarcinoma with FGFR2 gene fusion

Researchers develop an animal model of Marburg virus infection

Gilead provides remdesivir for use in response to novel coronavirus

FDA approves Palforzia oral immunotherapy for peanut allergy

Corvus offers new data from ongoing phase I/Ib trial of CPI-818 in advanced T-cell lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...